# Validation of Dihydroorotate Dehydrogenase as a Therapeutic Target in Mesothelioma

> **NIH VA I21** · MINNEAPOLIS VA  MEDICAL CENTER · 2024 · —

## Abstract

The Problem: Mesothelioma is a devastating cancer where the majority of patients will die from their disease.
The last significant advance in treatment for mesothelioma was the introduction of immunotherapy, which was
approved by the FDA in 2020. However, the benefits of current systemic therapeutic approaches to mesothelioma
are modest and not curative. New treatments are needed.
Knowledge to be Addressed: The long-term goal of this laboratory is to identify key principles of cancer
biology that will allow the appropriate selection of the most effective combination therapies based on upfront
molecular signatures. The objective of this application as a next step in the pursuit of this long-term goal is to
validate that dihydroorotate dehydrogenase (DHODH) is a viable target to inhibit as part of a treatment strategy
against mesothelioma. DHODH is a key (and rate-limiting) enzyme in de novo pyrimidine synthesis and has
been demonstrated to be highly expressed in several cancers, including mesothelioma.
Hypothesis: Our central hypothesis is that inhibition of DHODH will result in decreased cell proliferation in vitro
and decreased tumor growth in vivo. Secondarily, we also hypothesize that 1) combination treatment with DHODH
inhibition plus dinaciclib (inhibitor of CDKs 1, 2, 5, and 9 and 2) combination treatment with DHODH inhibition with
immune checkpoint inhibition will result in synergistic effects on cell proliferation in vitro and tumor growth in vivo.
Preliminary Studies: We have demonstrated that the DHODH inhibitor BAY2402234 potently inhibits
mesothelioma cell proliferation in vitro. In addition, we have demonstrated that the combination of
BAY2402334 and dinaciclib is synergistic in decreasing cell proliferation in vitro.
Specific aims: 1) Validate that inhibition of DHODH inhibits mesothelioma growth and proliferation. 2) Identify the
mechanisms of DHODH inhibition on related targetable pathways in mesothelioma to validate a drug combination
to inform the design of a near-term clinical trial.
Significance and Innovation: The proposed work is innovative because inhibition of DHODH has never been
studied in mesothelioma before. Positive results in this study will validate DHODH as a target to purse in treatment
strategies against mesothelioma. In addition, establishing a link between pyrimidine synthesis, several CDKs, and
immune checkpoint inhibition will be novel. The proposed research will de-risk future preclinical and clinical studies
and will aid in the design a clinical trial evaluating the effectiveness of DHODH inhibition in the treatment of
mesothelioma.

## Key facts

- **NIH application ID:** 10805764
- **Project number:** 1I21BX005935-01A2
- **Recipient organization:** MINNEAPOLIS VA  MEDICAL CENTER
- **Principal Investigator:** Mark A. Klein
- **Activity code:** I21 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2024
- **Award amount:** —
- **Award type:** 1
- **Project period:** 2024-05-01 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10805764

## Citation

> US National Institutes of Health, RePORTER application 10805764, Validation of Dihydroorotate Dehydrogenase as a Therapeutic Target in Mesothelioma (1I21BX005935-01A2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10805764. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*